Abstract
Host defense against invasion of Aspergillus spp. relies on effective phagocytosis by neutrophils and macrophages [1]. Accordingly, surveillance mainly focuses on leukaemia patients receiving myeloablative therapies in which the risk for invasive aspergillosis (IA) starts to rise drastically after 10 days of neutropenia. However, IA is occasionally observed in non-neutropenic patients who have some underlying disease or who receive immunosuppressive therapy that does not impair neutrophil counts [2–5].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
